{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT-322", "query": { "intervention": "CT-322" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T08:39:27.800Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00562419", "title": "CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "CT-322", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adnexus, A Bristol-Myers Squibb R&D Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2007-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2010-10-27", "last_synced_at": "2026-09-04T08:39:27.800Z", "location_count": 10, "location_summary": "La Jolla, California • Lexington, Kentucky • Boston, Massachusetts + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562419" }, { "nct_id": "NCT00851045", "title": "Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-Fluorouracil (bolus)", "type": "DRUG" }, { "name": "5-Fluorouracil (infusional)", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "CT-322", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Bevacizumab Placebo (saline solution)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-10", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-04T08:39:27.800Z", "location_count": 12, "location_summary": "Tucson, Arizona • Fountain Valley, California • Riverside, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00851045" }, { "nct_id": "NCT00374179", "title": "CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "CT-322", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adnexus, A Bristol-Myers Squibb R&D Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-08", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2009-02-24", "last_synced_at": "2026-09-04T08:39:27.800Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • San Antonio, Texas", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00374179" }, { "nct_id": "NCT00850577", "title": "Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "CT-322", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Bevacizumab placebo (ie saline solution)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 255, "start_date": "2009-06", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-04T08:39:27.800Z", "location_count": 20, "location_summary": "Tucson, Arizona • San Diego, California • Orlando, Florida + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00850577" }, { "nct_id": "NCT00768911", "title": "CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "CT-322", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Adnexus, A Bristol-Myers Squibb R&D Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-10", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2010-10-27", "last_synced_at": "2026-09-04T08:39:27.800Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768911" } ] }